Response to "Etiology and Management of Bleeding during ECMO in a COVID-19 Patient".
作者信息
Hayakawa Masaki, Matsumoto Masanori
机构信息
Department of Blood Transfusion Medicine, Nara Medical University.
出版信息
J Atheroscler Thromb. 2021 Apr 1;28(4):404-405. doi: 10.5551/jat.61747-R. Epub 2021 Jan 23.
Abstract
摘要
相似文献
1
Response to "Etiology and Management of Bleeding during ECMO in a COVID-19 Patient".对“一名新冠肺炎患者体外膜肺氧合期间出血的病因及处理”的回应
J Atheroscler Thromb. 2021 Apr 1;28(4):404-405. doi: 10.5551/jat.61747-R. Epub 2021 Jan 23.
2
Etiology and Management of Bleeding during ECMO in a COVID-19 Patient.一名新冠肺炎患者体外膜肺氧合期间出血的病因及处理
J Atheroscler Thromb. 2021 Apr 1;28(4):402-403. doi: 10.5551/jat.61747. Epub 2021 Jan 23.
3
Overcoming bleeding events related to extracorporeal membrane oxygenation in COVID-19.克服新型冠状病毒肺炎中与体外膜肺氧合相关的出血事件。
Lancet Respir Med. 2020 Dec;8(12):e87-e88. doi: 10.1016/S2213-2600(20)30467-7. Epub 2020 Oct 29.
4
Overcoming bleeding events related to extracorporeal membrane oxygenation in COVID-19 - Authors' reply.克服与COVID-19体外膜肺氧合相关的出血事件——作者回复
Lancet Respir Med. 2020 Dec;8(12):e89. doi: 10.1016/S2213-2600(20)30468-9. Epub 2020 Oct 29.
5
Neurologically Devastating Intraparenchymal Hemorrhage in COVID-19 Patients on Extracorporeal Membrane Oxygenation: A Case Series.COVID-19 患者体外膜肺氧合治疗期间并发神经破坏性脑实质内出血：病例系列研究。
Neurosurgery. 2020 Aug 1;87(2):E147-E151. doi: 10.1093/neuros/nyaa198.
6
Oropharyngeal hemorrhage in patients with COVID-19: A multi-institutional case series.COVID-19 患者的咽后出血：多机构病例系列。
Am J Otolaryngol. 2020 Nov-Dec;41(6):102691. doi: 10.1016/j.amjoto.2020.102691. Epub 2020 Aug 19.
7
A Case of Extracorporeal Membrane Oxygenation as a Salvage Therapy for COVID-19-Associated Severe Acute Respiratory Distress Syndrome: Mounting Evidence.1例体外膜肺氧合作为COVID-19相关严重急性呼吸窘迫综合征挽救治疗的病例：越来越多的证据
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620957778. doi: 10.1177/2324709620957778.
8
Recommendations for extracorporeal membrane oxygenation (ECMO) in COVID-19 patients : Consensus paper of the Medical University of Vienna.关于 COVID-19 患者体外膜肺氧合（ECMO）的建议：维也纳医科大学共识文件。
Wien Klin Wochenschr. 2020 Nov;132(21-22):671-676. doi: 10.1007/s00508-020-01708-8. Epub 2020 Jul 3.
9
Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation.严重 COVID-19 患者体外膜肺氧合抗凝管理。
J Cardiothorac Vasc Anesth. 2021 Feb;35(2):389-397. doi: 10.1053/j.jvca.2020.08.067. Epub 2020 Sep 4.
10
Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19.COVID-19 患者行静脉-静脉体外膜肺氧合时的血栓性回路并发症。
J Thromb Thrombolysis. 2021 Feb;51(2):301-307. doi: 10.1007/s11239-020-02217-1.
本文引用的文献
1
Etiology and Management of Bleeding during ECMO in a COVID-19 Patient.一名新冠肺炎患者体外膜肺氧合期间出血的病因及处理
J Atheroscler Thromb. 2021 Apr 1;28(4):402-403. doi: 10.5551/jat.61747. Epub 2021 Jan 23.
2
Management of a COVID-19 Patient during ECMO: Paying Attention to Acquired von Willebrand Syndrome.COVID-19 患者在体外膜肺氧合（ECMO）治疗期间的管理：注意获得性血管性血友病。
J Atheroscler Thromb. 2021 Apr 1;28(4):396-401. doi: 10.5551/jat.58362. Epub 2020 Oct 28.
3
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study.体外膜肺氧合治疗 COVID-19 相关严重急性呼吸窘迫综合征的回顾性队列研究。
Lancet Respir Med. 2020 Nov;8(11):1121-1131. doi: 10.1016/S2213-2600(20)30328-3. Epub 2020 Aug 13.
4
5
Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.关于弥散性血管内凝血的定义、临床及实验室标准和评分系统
Thromb Haemost. 2001 Nov;86(5):1327-30.
6
Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments.甲磺纳法莫司他（FUT-175）的药理学研究。I. 体内外实验中对蛋白酶活性的抑制作用
Jpn J Pharmacol. 1984 Jul;35(3):203-27. doi: 10.1254/jjp.35.203.
Zotero 插件